 |
Breast Cancer Management: Updates in Adjuvant Endocrine Therapy and Bisphosphonates for Early-Stage Disease
CHRISTINA I. HEROLD, MD
CAREY K. ANDERS, MD
KIMBERLY L. BLACKWELL, MD
APRIL, 2009 |
 |
Current Concepts in the Prevention of Venous Thromboembolism
Venous thromboembolism
(VTE), comprised of deep vein
thrombosis (DVT) and pulmonary
embolism (PE), is a major cause of death,
disability, and economic burden worldwide.
VTE afflicts millions of individuals and
accounts for several hundred thousand
deaths annually in the United States.
FEBRUARY, 2009 |
 |
Carbapenem Antibiotics: Maximizing Response and Minimizing Resistance
ROBERT P. RAPP, PHARMD, FCCP
CRAIG MARTIN, PHARMD
OCTOBER, 2008 |
 |
Guidelines for the Prevention Of Medication Errors
INSTITUTE FOR SAFE MEDICATION PRACTICES
OCTOBER, 2008 |
 |
Current Concepts in the Prevention of Venous Thromboembolism
KAREN FIUMARA, PHARMD
MATTHEW MACHADO, PHARMD
JOHN FANIKOS, RPH
OCTOBER, 2008 |
 |
Breast Cancer Management: Updates in Adjuvant Chemotherapy For Early-Stage Disease
With an estimated 182,460 new cases and 40,480 related
deaths in 2008, breast cancer remains the most common
malignancy among US women and the second most lethal.
During the 1980s, annual increases in the rate of breast cancer of
approximately 3.7% were largely attributed to the widespread
adoption of screening mammography.
OCTOBER, 2008 |
 |
The Medical Treatment of Metastatic Colorectal Cancer
Colorectal cancer is the third leading cause of cancer
deaths in men and women in the United States, with
an estimated total of 49,960 deaths in 2008. The high
number of deaths can be attributed to the inability to achieve
cures in a substantial number of patients with metastatic disease.
AUGUST, 2008 |
 |
Management Of Breast Cancer: Advanced Disease and Novel Agents
For patients
with metastatic
breast cancer, the
goal of therapy is to
maximize quality of life while palliating
cancer-related symptoms. Many factors
must be considered when treatment
strategies are selected in this setting,
including type and
timing of prior therapy;
hormonal (estrogen
receptor [ER] and
progesterone receptor [PR]) status; ERBB2
(formerly HER2/neu) status; location and
extent of disease; and patient characteristics,
such as age and comorbidities.
MARCH, 2008 |
|